Endometrial Cancer Trial, Recruiting NCT06598176 Sponsor: Universiteit Antwerpen Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06598176
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are female and between 25 and 64 years old
  • People who have been diagnosed with cervical cancer (CIN3 or above, at any stage) or who need a procedure called a conization (a procedure to remove tissue from the cervix, for any reason)
  • People who have not yet started any form of cancer treatment before joining the study
  • People who are able to give written consent to participate
  • People who are able to understand the study information brochure and what the study involves

Who may not be able to join:

  • People who have had a hysterectomy (surgical removal of the uterus)
  • People who are pregnant or are within 6 weeks of giving birth
  • People who have received treatment for cervical cancer or pre-cancer within the 6 months before joining the study
  • People who are currently participating in another clinical trial that is testing a medical device, drug, or vaccine at the same time
  • People who are unable to give informed consent
  • People who have severe anaemia (very low red blood cell levels)
  • People who have received a blood transfusion within two weeks before the blood sample is collected for the study
  • People for whom giving a blood sample would pose a risk to their overall health
  • People who have tested positive for HIV, Hepatitis B, or Hepatitis C
  • People who have issues with alcohol or drug misuse
  • People who have any current or past condition or abnormality that, in the opinion of the trial doctor, could affect the study results or make participation not in the person's best interest (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wiebren Tjalma, MD, PhD, Universiteit Antwerpen

Phone: 032659130

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Universiteit Antwerpen
Registry
ClinicalTrials.gov
Start date
28 March 2024
Est. completion
28 February 2027

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Detection of (epi)genetic biomarkers for cervical cancer and precancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov